Clinical Trials Logo

Filter by:
NCT ID: NCT06141226 Recruiting - Clinical trials for Non-small-cell Lung Cancer

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Start date: April 12, 2023
Phase: Phase 2
Study type: Interventional

Objective to compare the efficacy and safety of TQB2450 injection combined with anlotinib and chemotherapy, and TQB2450 injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer subjects who failed to receive first-line chemotherapy combined with immunization, and to explore and evaluate biomarkers related to efficacy, mechanism of action / resistance mechanism, and safety.

NCT ID: NCT06141213 Recruiting - Clinical trials for Chromosome Aberrations

The Relationship Between Fetal Membrane Thickness and Fetal Chromosomal Aneuploidies

PLACE2102
Start date: October 1, 2021
Phase:
Study type: Observational

This observational study aims to recruit pregnant women between 18 to 24 weeks of gestation to investigate the relationship between amniotic membrane thickness and fetal chromosomal abnormalities. The primary objectives are to establish whether a correlation exists between the measured thickness of the amniotic membrane and the presence of chromosomal abnormalities in the fetus, and to determine a cutoff value for amniotic membrane thickness that could indicate an increased risk of such abnormalities. Additionally, the study seeks to assess whether the inclusion of amniotic membrane thickness as a biomarker can enhance the detection rate of non-invasive prenatal testing (NIPT) and nuchal translucency (NT) for chromosomal abnormalities.

NCT ID: NCT06141109 Recruiting - Safety Issues Clinical Trials

Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma

MB07133
Start date: January 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

An open-label, multi-dose clinical trial design was used to investigate the combination of MB07133 injection combined with Sintilimab in the treatment of primary liver cancer in phase I/IIa studies, including two phases of dose escalation and dose expansion,in order to evaluate the safety and efficacy of MB07133 injection combined with Sintilimab.

NCT ID: NCT06141096 Recruiting - Safety Issues Clinical Trials

MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma

MB07133
Start date: January 17, 2020
Phase: Phase 2
Study type: Interventional

A randomized, open, multicenter clinical trial design was adopted, planned to be conducted in three stages, with 91 participants expected to be included in the study to evaluate the efficacy, tolerance, and safety of different doses of MB07133 in the treatment of unresectable advanced primary liver cancer.

NCT ID: NCT06140992 Recruiting - DNA Methylation Clinical Trials

PaCIFiC-CUP Classifies Cancer of Unknown Primary

Start date: July 1, 2023
Phase:
Study type: Observational

This study aims to initially utilize machine learning on pan-cancer DNA methylation data from public databases to construct a DNA methylation classification model (PaCIFiC-CUP, pan-cancer integrated fingerprinting classifier of CUP) for diagnosing various types of cancer, particularly the primary site of cancer of unknown primary. The goal is to achieve diagnosis of cancer pathology type by analyzing the DNA methylation patterns of cancer specimens, thereby guiding subsequent precision treatment for cancer.

NCT ID: NCT06140966 Recruiting - Multiple Myeloma Clinical Trials

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Start date: October 20, 2023
Phase: Phase 2
Study type: Interventional

This study will assess whether the combination of daratumumab and carfilzomib-based Induction/Consolidation/Maintenance Therapy with ASCT improves the outcome of patients with ultra high-risk, newly diagnosed multiple myeloma

NCT ID: NCT06140836 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Start date: December 21, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).

NCT ID: NCT06140797 Recruiting - Frailty Syndrome Clinical Trials

Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery

PRACTICE
Start date: April 15, 2024
Phase: N/A
Study type: Interventional

With the extended life expectancy of the Chinese population and improvements in surgery and anesthesia techniques, the number of aged patients undergoing surgery has been increasing annually. However, safety, effectiveness, and quality of life of aged patients undergoing surgery are facing major challenges. This prospective, multi-center, randomized, controlled study aims to construct a prehabilitation combined with enhanced recovery after surgery program which includes pre-operative risk assessment and targeted intervention.

NCT ID: NCT06140732 Recruiting - Chemotherapy Effect Clinical Trials

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

Start date: October 30, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well Camrelizumab combined with Apatinib work in treating participants with chordoma that has spread to other places in the body, which may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT06140680 Recruiting - Physical Inactivity Clinical Trials

Intervention in Habit, Automatic Affective Evaluations and Physical Activity Among University Students

Start date: February 12, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the effectiveness of the LifelongU intervention in habit, automatic affective evaluation and physical activity among university students. The main questions aim to answer are: - What is the difference in habit, automatic affective evaluation and physical activity between the intervention and control groups? - What is the difference in habit, automatic affective evaluation and physical activity between the before and after intervention? Participants will attend 12 sessions of four modules that performed face-to-face physical education lessons. Lesson content included 10-min health-related fitness knowledge, 30-min fitness test and training, 50-min motor skill training with behavior change techniques (90 min per a lesson, once a week). Researchers will compare control group to see if any effect difference.